Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Phase 2

3(75.0%)

Phase 1

1(25.0%)

4Total

Phase 2(3)

Phase 1(1)

Loading network data...

Showing 5 of 5 trials

Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC

Role: lead

Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies

Role: lead

Clinical Study of Individualized Treatment of Relapsed or Drug-resistant Advanced Gynecological Tumors Guided by PTC Model

Role: lead

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Role: lead

Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients

Role: lead

All 5 trials loaded